|
|
TechnoVax has three initial complementary goals
- Improve our current base technology:
- Advance our primary vaccine candidates into human clinical;
- Evolve and refine our proprietary VLP platform technology to support cost effective .and large scale production;
- Develop combination vaccines blending VLPs carrying antigens of different viral .pathogens on their surfaces (multiple virus protection in one vaccine product.)
- Expand our product pipeline
- Respiratory viral targets
- HIV and cancer vaccines
- Hemorragic fevers
- Seek commercial partnerships
- At regional level;
- Product centered;
- Project oriented;
| |
By achieving these goals, TechnoVax will be extremely well positioned to generate new technologies and products for commercialization and out-licensing.
|
|
|
|
Presentación en Español